XNCR

Company Overview — What Does Xencor Inc Do?

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Its product candidates include Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. In addition, it is developing VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. Further, the company is developing AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California. Xencor Inc (XNCR) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Bassil I. Dahiyat and employs approximately 280 people, headquartered in Monrovia, California. With a market capitalization of $919M, XNCR is one of the notable companies in the Healthcare sector.

Xencor Inc (XNCR) Stock Rating — Reduce (April 2026)

As of April 2026, Xencor Inc receives a Reduce rating with a composite score of 31.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.XNCR ranks #2,699 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Xencor Inc ranks #364 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

XNCR Stock Price and 52-Week Range

Xencor Inc (XNCR) currently trades at $12.42. The stock lost $0.11 (0.9%) in the most recent trading session. The 52-week high for XNCR is $18.69, which means the stock is currently trading -33.5% from its annual peak. The 52-week low is $6.92, putting the stock 79.5% above its annual trough. Recent trading volume was 530K shares, suggesting relatively thin trading activity.

Is XNCR Overvalued or Undervalued? — Valuation Analysis

Xencor Inc (XNCR) carries a value factor score of 20/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.42x, versus the sector average of 2.75x. The price-to-sales ratio is 8.36x, compared to 1.66x for the average Healthcare stock.

At current multiples, Xencor Inc trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Xencor Inc Profitability — ROE, Margins, and Quality Score

Xencor Inc (XNCR) earns a quality factor score of 29/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -20.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -15.0% versus the sector average of -33.1%.

On a margin basis, Xencor Inc reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -254.0% (sector: -66.1%). Net profit margin stands at -170.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 23.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

XNCR Debt, Balance Sheet, and Financial Health

Xencor Inc has a debt-to-equity ratio of 38.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 6.25x, indicating strong short-term liquidity. Total debt on the balance sheet is $133M. Cash and equivalents stand at $28M.

XNCR has a beta of 1.55, meaning it is more volatile than the broader market — a $10,000 investment in XNCR would be expected to move 54.7% more than the S&P 500 on any given day. The stability factor score for Xencor Inc is 29/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Xencor Inc Revenue and Earnings History — Quarterly Trend

In TTM 2026, Xencor Inc reported revenue of $108M and earnings per share (EPS) of $-1.24. Net income for the quarter was $-132M. Gross margin was 100.0%. Operating income came in at $-186M.

In FY 2025, Xencor Inc reported revenue of $126M and earnings per share (EPS) of $-1.24. Net income for the quarter was $-92M. Revenue grew 13.7% year-over-year compared to FY 2024. Operating income came in at $-178M.

In Q3 2025, Xencor Inc reported revenue of $21M and earnings per share (EPS) of $-0.08. Net income for the quarter was $-6M. Revenue grew 96.1% year-over-year compared to Q3 2024. Operating income came in at $-48M.

In Q2 2025, Xencor Inc reported revenue of $44M and earnings per share (EPS) of $-0.41. Net income for the quarter was $-31M. Revenue grew 157.1% year-over-year compared to Q2 2024. Operating income came in at $-33M.

Over the past 8 quarters, Xencor Inc has demonstrated a growth trajectory, with revenue expanding from $17M to $108M. Investors analyzing XNCR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

XNCR Dividend Yield and Income Analysis

Xencor Inc (XNCR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

XNCR Momentum and Technical Analysis Profile

Xencor Inc (XNCR) has a momentum factor score of 40/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 47/100 reflects moderate short selling activity.

XNCR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Xencor Inc (XNCR) ranks #364 out of 838 stocks based on the Blank Capital composite score. This places XNCR in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing XNCR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full XNCR vs S&P 500 (SPY) comparison to assess how Xencor Inc stacks up against the broader market across all factor dimensions.

XNCR Next Earnings Date

No upcoming earnings date has been announced for Xencor Inc (XNCR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy XNCR? — Investment Thesis Summary

The quantitative profile for Xencor Inc suggests caution. The quality score of 29/100 flags below-average profitability. The value score of 20/100 indicates premium valuation. High volatility (stability score 29/100) increases portfolio risk.

In summary, Xencor Inc (XNCR) earns a Reduce rating with a composite score of 31.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on XNCR stock.

Related Resources for XNCR Investors

Explore more research and tools: XNCR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare XNCR head-to-head with peers: XNCR vs AZN, XNCR vs SLGL, XNCR vs VMD.